[
  {
    "ts": null,
    "headline": "What Might Stock Markets Do If The FOMC Cuts Rates By Only 25 Bps",
    "summary": "With the FOMC around the corner, get the latest on Fed rate cut expectations for September 2025, market risks, inflation trends, and labor data.",
    "url": "https://finnhub.io/api/news?id=0f5e00e818668adf8071df8eed8133139f5be0bf4961ce979e012ff968ad1d62",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757696432,
      "headline": "What Might Stock Markets Do If The FOMC Cuts Rates By Only 25 Bps",
      "id": 136728566,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212921515/image_2212921515.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "With the FOMC around the corner, get the latest on Fed rate cut expectations for September 2025, market risks, inflation trends, and labor data.",
      "url": "https://finnhub.io/api/news?id=0f5e00e818668adf8071df8eed8133139f5be0bf4961ce979e012ff968ad1d62"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock",
    "summary": "ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.",
    "url": "https://finnhub.io/api/news?id=a1ec1ae61613d11406cd0066252bff369cc80a2884208951370aaa6a6b53b448",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757686860,
      "headline": "AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock",
      "id": 136726544,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.",
      "url": "https://finnhub.io/api/news?id=a1ec1ae61613d11406cd0066252bff369cc80a2884208951370aaa6a6b53b448"
    }
  },
  {
    "ts": null,
    "headline": "This Under-the-Radar Healthcare Stock Could Soar in 2026",
    "summary": "We should know a lot more by year-end.",
    "url": "https://finnhub.io/api/news?id=9b636b7acb5d7a4a62fd87bc2db36380a2077dcc8594bd0937a79c0af8a2a3e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757682900,
      "headline": "This Under-the-Radar Healthcare Stock Could Soar in 2026",
      "id": 136711229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We should know a lot more by year-end.",
      "url": "https://finnhub.io/api/news?id=9b636b7acb5d7a4a62fd87bc2db36380a2077dcc8594bd0937a79c0af8a2a3e2"
    }
  },
  {
    "ts": null,
    "headline": "Takeda poaches top Lilly exec; Maze soars on early PKU drug data",
    "summary": "Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in court.",
    "url": "https://finnhub.io/api/news?id=72776c380d68e6e5b3343bfd2f163504b0db44cbdd222a5df8dc2c3db467bbe9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757677500,
      "headline": "Takeda poaches top Lilly exec; Maze soars on early PKU drug data",
      "id": 136726545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in court.",
      "url": "https://finnhub.io/api/news?id=72776c380d68e6e5b3343bfd2f163504b0db44cbdd222a5df8dc2c3db467bbe9"
    }
  },
  {
    "ts": null,
    "headline": "Weekly Recap: 9 Tech Press Releases You Need to See",
    "summary": "With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.",
    "url": "https://finnhub.io/api/news?id=40bd63fb56c87be2604b23ec3b5eaf5059eb708539ef8fb8ad2651e904bcde8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757676120,
      "headline": "Weekly Recap: 9 Tech Press Releases You Need to See",
      "id": 136711230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.",
      "url": "https://finnhub.io/api/news?id=40bd63fb56c87be2604b23ec3b5eaf5059eb708539ef8fb8ad2651e904bcde8c"
    }
  },
  {
    "ts": null,
    "headline": "1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street",
    "summary": "The positives for this big drugmaker appear to outweigh the negatives.",
    "url": "https://finnhub.io/api/news?id=3e54a496e8a22323e1603256aba21aa6d30373006430f57832055fbbb5675e17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757670240,
      "headline": "1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street",
      "id": 136711231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The positives for this big drugmaker appear to outweigh the negatives.",
      "url": "https://finnhub.io/api/news?id=3e54a496e8a22323e1603256aba21aa6d30373006430f57832055fbbb5675e17"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl",
    "summary": "For U.S. Big Pharma companies, vaccines have largely been an afterthought. But by 2030, they could be a quarter of Pfizer’s revenue.",
    "url": "https://finnhub.io/api/news?id=c9856317978cc0374201e534ece3e531bd07b9ea156ab6692f3248a096ffc96a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757664000,
      "headline": "Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl",
      "id": 136711232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "For U.S. Big Pharma companies, vaccines have largely been an afterthought. But by 2030, they could be a quarter of Pfizer’s revenue.",
      "url": "https://finnhub.io/api/news?id=c9856317978cc0374201e534ece3e531bd07b9ea156ab6692f3248a096ffc96a"
    }
  }
]